member
coronaviru
famili
respons
current
pandem
base
analysi
hepat
c
viru
coronaviru
replic
molecular
structur
activ
viral
inhibitor
previous
demonstr
three
nucleotid
analogu
inhibit
sarscov
rnadepend
rna
polymeras
rdrp
use
polymeras
extens
experi
demonstr
activ
triphosph
form
sofosbuvir
key
compon
fda
approv
hepat
c
drug
epclusa
incorpor
rdrp
block
incorpor
use
molecular
insight
select
activ
triphosph
form
three
antivir
agent
alovudin
azt
fda
approv
hivaid
drug
tenofovir
alafenamid
taf
fda
approv
drug
hiv
hepat
b
evalu
inhibitor
rdrp
demonstr
abil
three
viral
polymeras
inhibitor
triphosph
triphosph
tenofovir
diphosph
activ
triphosph
form
alovudin
azt
taf
respect
incorpor
rdrp
also
termin
polymeras
extens
result
offer
strong
molecular
basi
nucleotid
analogu
evalu
potenti
therapeut
pandem
caus
spread
countri
contin
new
member
subgenu
sarbecoviru
orthocoronavirina
subfamili
distinct
merscov
sarscov
coronavirus
singlestrand
rna
virus
share
properti
singlestrand
rna
virus
hepat
c
viru
hcv
west
nile
viru
marburg
viru
hiv
viru
ebola
viru
dengu
viru
rhinovirus
coronavirus
like
hcv
flavivirus
positivesens
singlestrand
rna
virus
virus
share
similar
replic
mechan
requir
rnadepend
rna
polymeras
rdrp
potenti
inhibitor
design
target
nearli
everi
stage
viral
replic
cycl
howev
despit
decad
research
effect
drug
current
approv
treat
seriou
coronaviru
infect
sar
mer
one
import
druggabl
target
coronavirus
rdrp
polymeras
display
similar
catalyt
mechan
key
conserv
amino
acid
activ
site
among
differ
posit
sens
rna
virus
coronavirus
hcv
belong
like
rdrp
virus
coronaviru
enzym
highli
errorpron
might
increas
abil
accept
modifi
nucleotid
analogu
substrat
nucleotid
nucleosid
analogu
inhibit
polymeras
import
group
antivir
agent
base
analysi
hepat
c
viru
coronaviru
replic
molecular
structur
activ
viral
inhibitor
previous
demonstr
three
nucleotid
analogu
inhibit
sarscov
rnadepend
rna
polymeras
rdrp
use
polymeras
extens
experi
demonstr
activ
triphosph
form
sofosbuvir
incorpor
sarscov
rdrp
block
incorpor
use
molecular
insight
select
two
antivir
agent
alovudin
azt
first
fda
approv
hivaid
drug
evalu
inhibitor
sarscov
rdrp
alovudin
azt
share
similar
backbon
structur
base
ribos
sofosbuvir
fewer
modif
site
less
steric
hindranc
furthermor
modif
alovudin
azt
carbon
place
oh
group
directli
prevent
incorpor
nucleotid
lead
perman
termin
rna
synthesi
replic
viru
also
demonstr
abil
two
hiv
revers
transcriptas
inhibitor
triphosph
triphosph
activ
triphosph
form
alovudin
azt
incorpor
sarscov
rdrp
also
termin
polymeras
extens
paper
first
construct
rdrp
base
similar
procedur
sarscov
demonstr
three
nucleotid
analogu
fig
b
inhibitor
rdrp
use
structureact
base
molecular
insight
select
activ
triphosph
form
tenofovir
alafenamid
taf
vemlidi
acycl
adenosin
nucleotid
fig
c
fda
approv
drug
hiv
hepat
b
viru
hbv
infect
evalu
rdrp
inhibitor
result
indic
activ
triphosph
form
molecul
tenofovir
diphosph
tfvdp
also
inhibit
polymeras
taf
prodrug
form
nucleotid
analogu
viral
polymeras
inhibitor
show
potent
activ
hiv
hbv
limit
inhibit
host
nuclear
mitochondri
polymeras
activ
seri
hydrolas
deprotect
monophosph
form
tfv
two
consecut
kinas
reaction
tfvdp
tfvdp
acycl
nucleotid
group
remark
molecul
incorpor
hiv
hbv
polymeras
termin
nucleic
acid
elong
viral
replic
addit
resist
mutat
rare
seen
patient
treat
regimen
includ
taf
view
fact
activ
triphosph
form
taf
tenofovir
diphosph
much
smaller
natur
nucleosid
triphosph
expect
easili
fit
within
activ
site
rdrp
noncycl
nucleotid
tfvdp
lack
normal
sugar
ring
configur
thu
reason
unlik
recogn
ccbyncnd
intern
licens
authorfund
made
avail
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
exonucleas
involv
proofread
process
decreas
likelihood
develop
resist
drug
given
amino
acid
similar
sarscov
rdrp
reason
four
nucleotid
analogu
list
fig
would
also
inhibit
polymeras
thu
assess
abil
meutp
tfvdp
dttp
activ
triphosph
form
sofosbuvir
alovudin
taf
azt
respect
incorpor
rdrp
rna
primer
termin
polymeras
reaction
rdrp
refer
two
protein
cofactor
whose
homolog
shown
requir
process
polymeras
activ
sarscov
clone
purifi
describ
method
three
viral
gene
product
high
homolog
eg
ident
similar
similar
homolog
level
amino
acid
level
equival
gene
product
sarscov
caus
agent
sar
perform
polymeras
extens
assay
meutp
dttp
tfvdp
utp
follow
addit
preanneal
rna
templat
primer
preassembl
mixtur
rdrp
two
cofactor
protein
extend
primer
product
reaction
subject
malditofm
analysi
rna
templat
primer
correspond
end
genom
use
polymeras
assay
sequenc
indic
top
fig
two
row
next
avail
posit
templat
rna
polymeras
extens
downstream
prime
site
meutp
dttp
incorpor
viral
rdrp
singl
nucleotid
analogu
ad
primer
strand
inde
inhibitor
polymeras
extens
stop
incorpor
prevent
two
templat
follow
u
case
tfvdputp
mixtur
two
utp
incorpor
prior
incorpor
termin
tfvdp
adenosin
base
shown
fig
exactli
observ
malditof
ms
trace
fig
peak
indic
molecular
weight
singl
base
primer
extens
product
one
meutp
obtain
da
observ
da
expect
similarli
trace
fig
singl
extens
peak
indic
singl
base
extens
reveal
da
observ
da
expect
incorpor
case
primer
nearli
complet
extend
trace
fig
singl
extens
peak
indic
singlebas
extens
dttp
seen
da
observ
da
expect
evid
incorpor
though
incorpor
effici
lower
meutp
may
requir
optim
final
trace
fig
peak
indic
molecular
weight
primer
extens
product
form
incorpor
u
tfv
found
da
observ
da
expect
addit
peak
repres
partial
incorpor
u
da
observ
da
expect
misincorpor
u
da
observ
da
expect
importantli
tfvdp
incorpor
extens
indic
perman
termin
summari
result
demonstr
nucleotid
analogu
meutp
dttp
tfvdp
perman
termin
rdrp
prodrug
version
sofosbuvir
dt
nucleosid
dt
nucleosid
taf
avail
readili
synthes
use
protid
prodrug
approach
shown
fig
ad
develop
therapeut
importantli
sinc
sofosbuvir
tenofovir
azt
wide
ccbyncnd
intern
licens
authorfund
made
avail
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
avail
fda
approv
drug
evalu
quickli
laboratori
clinic
set
treatment
termin
polymeras
reaction
sequenc
primer
templat
use
extens
reaction
end
genom
shown
top
figur
polymeras
extens
reaction
perform
incub
meutp
b
c
utp
tfvdp
dttp
preassembl
polymeras
indic
rna
templat
primer
appropri
reaction
buffer
follow
detect
reaction
product
malditof
ms
detail
procedur
shown
method
section
accuraci
mz
determin
da
gene
codon
optim
clone
pfastbac
ctermin
addit
tev
site
strep
tag
genscript
pfastbac
plasmid
e
coli
life
technolog
use
creat
recombin
bacmid
bacmid
transfect
cell
express
system
cellfectin
ii
life
technolog
gener
recombin
baculoviru
baculoviru
amplifi
two
passag
cell
use
infect
l
cell
express
system
incub
hr
cell
harvest
centrifug
resuspend
ccbyncnd
intern
licens
authorfund
made
avail
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
wash
buffer
mm
hepe
ph
mm
nacl
mm
mgcl
mm
dtt
biolock
per
liter
cultur
cell
lyse
via
microfluid
microfluid
lysat
clear
centrifug
filtrat
protein
purifi
use
strep
tactin
superflow
agaros
iba
strep
tactin
elut
protein
purifi
size
exclus
chromatographi
use
superdex
increas
column
ge
life
scienc
mm
hepe
mm
nacl
mgcl
mm
tcep
ph
pure
protein
concentr
ultrafiltr
prior
flash
freez
liquid
nitrogen
gene
codon
optim
clone
novagen
ntermin
histidin
tag
enterokinas
site
tev
proteas
site
pli
e
coli
cell
novagen
use
bacteri
express
induct
isopropyl
iptg
cultur
grown
hr
cell
harvest
centrifug
pellet
resuspend
wash
buffer
tri
ph
mm
nacl
mm
imidazol
mm
dtt
cell
lyse
via
microfluid
lysat
clear
centrifug
filtrat
protein
purifi
use
ninta
agaros
bead
elut
wash
buffer
contain
mm
imidazol
elut
protein
purifi
size
exclus
chromatographi
use
superdex
increas
column
ge
life
scienc
purifi
protein
concentr
ultrafiltr
prior
flash
freez
liquid
nitrogen
extens
reaction
rnadepend
rna
polymeras
oligonucleotid
purchas
idt
inc
primer
templat
sequenc
shown
fig
anneal
heat
min
cool
room
temperatur
reaction
buffer
rna
polymeras
mixtur
consist
cofactor
incub
min
room
temperatur
ratio
reaction
buffer
anneal
templat
primer
solut
contain
templat
primer
reaction
buffer
ad
rna
polymeras
mixtur
incub
addit
min
room
temperatur
final
solut
contain
either
mm
meutp
mm
b
mm
tfvdp
utp
c
dttp
reaction
buffer
ad
incub
carri
hr
final
concentr
reagent
extens
reaction
nm
rna
primer
nm
rna
templat
either
meutp
sierra
bioresearch
amersham
life
scienc
utp
dttp
amersham
life
scienc
reaction
buffer
mm
trishcl
ph
mm
kcl
mm
mgcl
mm
follow
desalt
use
oligo
clean
concentr
zymo
research
sampl
subject
malditofm
bruker
ultraflextrem
analysi
ccbyncnd
intern
licens
authorfund
made
avail
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
